Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages

Company Data

Name Jyong Biotech Ltd. - Ordinary shares

Company Jyong Biotech Ltd. Ordinary Shares

Symbol MENS

Website https://www.jyongbio.com/

Primary Exchange

NASDAQ

ISIN KYG831161065

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Kuo Fu-Feng

Market Capitalization 3 Mrd.

Country Taiwan

Currency USD

Employees 0,0 T

Address 23F‑3, No. 95, Section 1, Xintai 5th Road, 221 New Taipei City

IPO Date 2025-06-17

Ticker Symbols

Name	Symbol
NASDAQ	MENS

More Shares

Investors who hold Jyong Biotech Ltd. - Ordinary shares also have the following shares in their portfolio:

BIO-TECHNOLOGIES CORP Share

SANTAN.UK GRP 17/28 FLR Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog